RGNX REGENXBIO Inc.

32.85
+0.85  (3%)
Previous Close 32.00
Open 32.40
Price To book 4.80
Market Cap 1016672778
Shares 30,948,943
Volume 201,578
Short Ratio 2.24
Av. Daily Volume 363,817

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 dosing initiated - March 8, 2017. Interim data due by the end of 2017.
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2 enrollment to be initiated 1H 2018.
RGX-111
Mucopolysaccharidosis Type I (MPS I)

Latest News

  1. Gene Therapies: A Foot in the Door
  2. ETFs with exposure to REGENXBIO, Inc. : October 9, 2017
  3. REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
  4. ​After bidding war, North Bay drug maker snags gene therapy company for $151 million
  5. ​After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout
  6. Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers
  7. Ultragenyx to Acquire Dimension Therapeutics
  8. REGENXBIO to Present at Upcoming Investor Conferences
  9. RegenxBio declines to push forward on planned acquisition
  10. REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics
  11. Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”
  12. 8 Stocks for the Next Gene Revolution
  13. Edited Transcript of RGNX earnings conference call or presentation 8-Aug-17 8:30pm GMT
  14. Gene Therapy: A Big Week for Many Names
  15. [$$] Gene Therapy Is Nearing a Major Breakthrough
  16. REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
  17. Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
  18. Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
  19. UPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid
  20. Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers